プロフィール詳細

プロジェクトを作成

★★★★★

☆☆☆☆☆

★★★★★

☆☆☆☆☆

William S.に依頼

United States

Biotech Consultant | IND Strategy, Biomarkers, Translational Research | Expert Guidance for Drug Development

プロフィール概要

Seasoned researcher highly experience in the fields of cell biology and oncology. Served as both lead and contributor to dedicated teams that successfully submitted several Investigational New Drug (IND) applications in multiple modalities (small molecule and RNA therapeutics) as well as a New Drug Application (NDA) to treat patients with relapsed / refractory multiple myeloma which garnered FDA-accelerated approval. Seeking an opportunity to discover novel targets and biomarkers to move oncology pipelines forward and improve patient selection and care.

専門分野

• ★ Biomarkers
• ★ Drug Discovery
• ★ Technical & Scientific Writing
• ☆ Molecular Biology
• ☆ Cell Biology
• ☆ Drug Target Identification
• ☆ Hit-to-Lead & Lead Optimization
• ☆ High Content Screening/Imaging
• ☆ Drug Design
• ☆ In vitro Diagnostics
• ☆ Biomarker Analysis
• ☆ Manuscript & Journal Article Writing
• ☆ Experimental Protocols
• ☆ SOP & Protocol Writing
• ☆ Science Communication

サービス

• Writing

Writing Clinical Trial Documentation, Medical Writing, Technical Writing

職務経験

Founder and Principal Consultant

BioTargeted Solutions LLC

3月 2025 - 現在

Senior Director, Cancer Biology

Omega Therapeutics, Inc

3月 2023 - 2月 2025

Director, Cancer Biology

Omega Therapeutics, Inc.

5月 2020 - 3月 2023

Clinical Research Scientist

Karyopharm Therapeutics (United States)

4月 2020 - 6月 2020

Senior Director, Research

resTORbio

8月 2019 - 1月 2020

Director, Research and Clinical Development

Karyopharm Therapeutics (United States)

7月 2017 - 8月 2019

Associate Director, Biology

Karyopharm Therapeutics (United States)

1月 2016 - 7月 2017

Senior Scientist, Biology

Karyopharm Therapeutics (United States)

12月 2011 - 1月 2016

Scientist, Biology

Karyopharm Therapeutics (United States)

3月 2011 - 12月 2011

Scientific Technician

Fox Chase Cancer Center

1月 2001 - 8月 2005

学歴

PhD in Cell Biology (Cell and Developmental Biology)

Harvard University

9月 2005 - 3月 2011

BS with Distinction in Biology and Minor in Chemistry (Biology)

Pennsylvania State University

1996 - 2000

認定資格

• 認定資格の詳細は未入力です。

出版物

JOURNAL ARTICLE

William Senapedis, Kayleigh M. Gallagher, Elmer Figueroa, Jeremiah D. Farelli, Robert Lyng, J. Graeme Hodgson, Charles W. O’Donnell, Joseph V. Newman, Madison Pacaro, Stephen K. Siecinski, et al. (2024). Targeted transcriptional downregulation of MYC using epigenomic controllers demonstrates antitumor activity in hepatocellular carcinoma models . Nature Communications.

Khan, H.Y., Nagasaka, M., Aboukameel, A., Alkhalili, O., Uddin, Md.H., Bannoura, S.F., Mzannar, Y., Azar, I., Beal, E.W., Tobon, M.E., et al.(2023). Anticancer Efficacy of KRAS^G12CInhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRAS^G12C-Mutant Pancreatic and Lung Cancers . Molecular Cancer Therapeutics. 22. (12). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 1422-1433.

Cornell, R.F., Baz, R., Richter, J.R., Rossi, A., Vogl, D.T., Chen, C., Shustik, C., Alvarez, M.J., Shen, Y., Unger, T.J., et al.(2022). A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma . American Journal of Hematology. 97. (2). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString E54-E58.

Khan, H.Y., Uddin, M.H., Balasubramanian, S.K., Sulaiman, N., Iqbal, M., Chaker, M., Aboukameel, A., Li, Y., Senapedis, W., Baloglu, E., et al.(2022). Pak4 and nampt as novel therapeutic targets in diffuse large b-cell lymphoma, follicular lymphoma, and mantle cell lymphoma . Cancers. 14. (1).

Mpilla, G.B., Uddin, Md.H., Al-Hallak, M.N., Aboukameel, A., Li, Y., Kim, S.H., Beydoun, R., Dyson, G., Baloglu, E., Senapedis, W.T., et al.(2021). PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus . Molecular Cancer Therapeutics. 20. (10). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 1836-1845.

Abril-Rodriguez, G., Torrejon, D.Y., Liu, W., Zaretsky, J.M., Nowicki, T.S., Tsoi, J., Puig-Saus, C., Baselga-Carretero, I., Medina, E., Quist, M.J., et al.(2020). Erratum: Publisher Correction: PAK4 inhibition improves PD-1 blockade immunotherapy (Nature cancer (2020) 1 1 (46-58)) . Nature cancer. 1. (2). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 264.

Abril-Rodriguez, G., Torrejon, D.Y., Liu, W., Zaretsky, J.M., Nowicki, T.S., Tsoi, J., Puig-Saus, C., Baselga-Carretero, I., Medina, E., Quist, M.J., et al.(2020). PAK4 inhibition improves PD-1 blockade immunotherapy . Nature Cancer. 1. (1). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 46-58.

Trott, J.F., Abu Aboud, O., McLaughlin, B., Anderson, K.L., Modiano, J.F., Kim, K., Jen, K.-Y., Senapedis, W., Chang, H., Landesman, Y., et al.(2020). Anti-Cancer Activity of PAK4/NAMPT Inhibitor and Programmed Cell Death Protein-1 Antibody in Kidney Cancer . Kidney360. 1. (5). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 376-388.

Fischer, M.A., Friedlander, S.Y., Arrate, M.P., Chang, H., Gorska, A.E., Fuller, L.D., Ramsey, H.E., Kashyap, T., Argueta, C., Debler, S., et al.(2020). Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies . Blood Advances. 4. (3). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 586-598.

Li, N., Lopez, M.A., Linares, M., Kumar, S., Oliva, S., Martinez-Lopez, J., Xu, L., Xu, Y., Perini, T., Senapedis, W., et al.(2019). Dual PAK4-NAMPT inhibition impacts growth and survival, and increases sensitivity to DNA-damaging agents in Waldenstrom ^€ macroglobulinemia . Clinical Cancer Research. 25. (1). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 369-377.

Sexton, R., Mahdi, Z., Chaudhury, R., Beydoun, R., Aboukameel, A., Khan, H.Y., Baloglu, E., Senapedis, W., Landesman, Y., Tesfaye, A., et al.(2019). Targeting nuclear exporter protein XPO1/CRM1 in gastric cancer . International Journal of Molecular Sciences. 20. (19).

Mpilla, G., Aboukameel, A., Muqbil, I., Kim, S., Beydoun, R., Philip, P.A., Mohammad, R.M., Kamgar, M., Shidham, V., Senapedis, W., et al.(2019). PAK4-NAMPT dual inhibition as a novel strategy for therapy resistant pancreatic neuroendocrine tumors . Cancers. 11. (12).

Mitchell, S.R., Larkin, K., Grieselhuber, N.R., Lai, T.-H., Cannon, M., Orwick, S., Sharma, P., Asemelash, Y., Zhang, P., Goettl, V.M., et al.(2019). Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia . Blood Advances. 3. (3). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 242-255.

Mohammad, R.M., Li, Y., Muqbil, I., Aboukameel, A., Senapedis, W., Baloglu, E., Landesman, Y., Philip, P.A., Azmi, A.S.(2019). Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarcinoma proliferation . Small GTPases. 10. (5). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 367-377.

Gandhi, U.H., Senapedis, W., Baloglu, E., Unger, T.J., Chari, A., Vogl, D., Cornell, R.F.(2018). Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma . Clinical Lymphoma, Myeloma and Leukemia. 18. (5). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 335-345.

Aboukameel, A., Muqbil, I., Baloglu, E., Senapedis, W., Landesman, Y., Argueta, C., Kauffman, M., Chang, H., Kashyap, T., Shacham, S., et al.(2018). Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression . Oncotarget. 9. (82). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 35327-35342.

Kashyap, T., Argueta, C., Unger, T., Klebanov, B., Debler, S., Senapedis, W., Crochiere, M.L., Lee, M.S., Kauffman, M., Shacham, S., et al.(2018). Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents . Oncotarget. 9. (56). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 30773-30786.

Argueta, C., Kashyap, T., Klebanov, B., Unger, T.J., Guo, C., Harrington, S., Baloglu, E., Lee, M., Senapedis, W., Shacham, S., et al.(2018). Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death . Oncotarget. 9. (39). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 25529-25544.

Neggers, J.E., Kwanten, B., Dierckx, T., Noguchi, H., Voet, A., Bral, L., Minner, K., Massant, B., Kint, N., Delforge, M., et al.(2018). Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes . Nature Communications. 9. (1).

Takao, S., Chien, W., Madan, V., Lin, D.-C., Ding, L.-W., Sun, Q.-Y., Mayakonda, A., Sudo, M., Xu, L., Chen, Y., et al.(2018). Targeting the vulnerability to NAD + depletion in B-cell acute lymphoblastic leukemia . Leukemia. 32. (3). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 616-625.

Rane, C.K., Patel, M., Cai, L., Senapedis, W., Baloglu, E., Minden, A.(2018). Decrypting the PAK4 transcriptome profile in mammary tumor forming cells using Next Generation Sequencing . Genomics. 110. (4). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 248-256.

Rane, C., Senapedis, W., Baloglu, E., Landesman, Y., Crochiere, M., Das-Gupta, S., Minden, A.(2017). A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth . Scientific Reports. 7.

Hwang, V.J., Zhou, X., Chen, X., Trott, J., Abu Aboud, O., Shim, K., Dionne, L.K., Chmiel, K.J., Senapedis, W., Baloglu, E., et al.(2017). Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease . Kidney International. 92. (4). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 922-933.

Azmi, A.S., Li, Y., Muqbil, I., Aboukameel, A., Senapedis, W., Baloglu, E., Landesman, Y., Shacham, S., Kauffman, M.G., Philip, P.A., et al.(2017). Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration . Oncotarget. 8. (47). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 82144-82155.

Fulciniti, M., Martinez-Lopez, J., Senapedis, W., Oliva, S., Bandi, R.L., Amodio, N., Xu, Y., Szalat, R., Gulla, A., Samur, M.K., et al.(2017). Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma . Blood. 129. (16). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 2233-2245.

Etchin, J., Berezovskaya, A., Conway, A.S., Galinsky, I.A., Stone, R.M., Baloglu, E., Senapedis, W., Landesman, Y., Kauffman, M., Shacham, S., et al.(2017). KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells . Leukemia. 31. (1). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 143-150.

Vercruysse, T., De Bie, J., Neggers, J.E., Jacquemyn, M., Vanstreels, E., Schmid-Burgk, J.L., Hornung, V., Baloglu, E., Landesman, Y., Senapedis, W., et al.(2017). The second-generation exportin-1 inhibitor KPT-8602 demonstrates potent activity against acute lymphoblastic leukemia . Clinical Cancer Research. 23. (10). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 2528-2541.

Aboukameel, A., Muqbil, I., Senapedis, W., Baloglu, E., Landesman, Y., Shacham, S., Kauffman, M., Philip, P.A., Mohammad, R.M., Azmi, A.S.(2017). Novel p21-activated kinase 4 (PAK4) allosteric modulators overcome drug resistance and stemness in pancreatic ductal adenocarcinoma . Molecular Cancer Therapeutics. 16. (1). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 76-87.

Jiang, Y.-Y., Lin, D.-C., Mayakonda, A., Hazawa, M., Ding, L.-W., Chien, W.-W., Xu, L., Chen, Y., Xiao, J.-F., Senapedis, W., et al.(2017). Targeting super-enhancer-Associated oncogenes in oesophageal squamous cell carcinoma . Gut. 66. (8). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 1358-1368.

Muqbil, I., Aboukameel, A., Elloul, S., Carlson, R., Senapedis, W., Baloglu, E., Kauffman, M., Shacham, S., Bhutani, D., Zonder, J., et al.(2016). Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone . Cancer Letters. 383. (2). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 309-317.

Kashyap, T., Argueta, C., Aboukameel, A., Unger, T.J., Klebanov, B., Mohammad, R.M., Muqbil, I., Azmi, A.S., Drolen, C., Senapedis, W., et al.(2016). Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death . Oncotarget. 7. (48). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 78883-78895.

Aboud, O.A., Chen, C.-H., Senapedis, W., Baloglu, E., Argueta, C., Weiss, R.H.(2016). Dual and specific inhibition of NAMPT and PAK4 by KPT-9274 decreases kidney cancer growth . Molecular Cancer Therapeutics. 15. (9). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 2119-2129.

Senapedis, W., Crochiere, M., Baloglu, E., Landesman, Y.(2016). Therapeutic potential of targeting PAK signaling . Anti-Cancer Agents in Medicinal Chemistry. 16. (1). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 75-88.

Taylor-Kashton, C., Lichtensztejn, D., Baloglu, E., Senapedis, W., Shacham, S., Kauffman, M.G., Kotb, R., Mai, S.(2016). XPO1 Inhibition Preferentially Disrupts the 3D Nuclear Organization of Telomeres in Tumor Cells . Journal of Cellular Physiology. 231. (12). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 2711-2719.

Ferreiro-Neira, I., Torres, N.E., Liesenfeld, L.F., Chan, C.H.F., Penson, T., Landesman, Y., Senapedis, W., Shacham, S., Hong, T.S., Cusack, J.C.(2016). XPO1 inhibition enhances radiation response in preclinical models of rectal cancer . Clinical Cancer Research. 22. (7). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 1663-1673.

Kim, J., McMillan, E., Kim, H.S., Venkateswaran, N., Makkar, G., Rodriguez-Canales, A., Villalobos, P., Neggers, J.E., Mendiratta, S., Wei, S., et al.(2016). XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer . Nature. 538. (7623). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 114-117.

Azmi, A.S., Muqbil, I., Wu, J., Aboukameel, A., Senapedis, W., Baloglu, E., Bollig-Fischer, A., Dyson, G., Kauffman, M., Landesman, Y., et al.(2015). Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition . Scientific Reports. 5.

Crochiere, M., Kashyap, T., Kalid, O., Shechter, S., Klebanov, B., Senapedis, W., Saint-Martin, J.-R., Landesman, Y.(2015). Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds . BMC Cancer. 15. (1).

Tai, Y.-T., Landesman, Y., Acharya, C., Calle, Y., Zhong, M.Y., Cea, M., Tannenbaum, D., Cagnetta, A., Reagan, M., Munshi, A.A., et al.(2014). CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: Molecular mechanisms and therapeutic implications . Leukemia. 28. (1). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 155-165.

Senapedis, W.T., Baloglu, E., Landesman, Y.(2014). Clinical translation of nuclear export inhibitors in cancer . Seminars in Cancer Biology. 27. Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 74-86.

Yang, J., Bill, M.A., Young, G.S., La Perle, K., Landesman, Y., Shacham, S., Kauffman, M., Senapedis, W., Kashyap, T., Saint-Martin, J.-R., et al.(2014). Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells . PLoS ONE. 9. (7).

Gravina, G.L., Senapedis, W., McCauley, D., Baloglu, E., Shacham, S., Festuccia, C.(2014). Nucleo-cytoplasmic transport as a therapeutic target of cancer . Journal of Hematology and Oncology. 7. (1).

Salas Fragomeni, R.A., Chung, H.W., Landesman, Y., Senapedis, W., Saint-Martin, J.-R., Tsao, H., Flaherty, K.T., Shacham, S., Kauffman, M., Cusack, J.C.(2013). CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma . Molecular Cancer Therapeutics. 12. (7). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 1171-1179.

Senapedis, W.T., Kennedy, C.J., Boyle, P.M., Silver, P.A.(2011). Whole genome siRNA cell-based screen links mitochondria to Akt signaling network through uncoupling of electron transport chain . Molecular Biology of the Cell. 22. (10). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 1791-1805.

Gómez-Baldó, L., Schmidt, S., Maxwell, C.A., Bonifaci, N., Gabaldón, T., Vidalain, P.-O., Senapedis, W., Kletke, A., Rosing, M., Barnekow, A., et al.(2010). TACC3-TSC2 maintains nuclear envelope structure and controls cell division . Cell Cycle. 9. (6). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 1143-1155.

Aldaye, F.A., Senapedis, W.T., Silver, P.A., Way, J.C.(2010). A structurally tunable DNA-based extracellular matrix . Journal of the American Chemical Society. 132. (42). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 14727-14729.

Astrinidis, A., Senapedis, W., Henske, E.P.(2006). Hamartin, the tuberous sclerosis complex 1 gene product, interacts with polo-like kinase 1 in a phosphorylation-dependent manner . Human Molecular Genetics. 15. (2). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 287-297.

Astrinidis, A., Senapedis, W., Coleman, T.R., Henske, E.P.(2003). Cell Cycle-regulated Phosphorylation of Hamartin, the Product of the Tuberous Sclerosis Complex 1 Gene, by Cyclin-dependent Kinase 1/Cyclin B . Journal of Biological Chemistry. 278. (51). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 51372-51379.

Khare, L., Astrinidis, A., Senapedis, W., Adams, P.D., Henske, E.P.(2002). Expression of wild type and mutant TSC2, but not TSC1, causes an increase in the G1 fraction of the cell cycle in HEK293 cells . Journal of Medical Genetics. 39. (9). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 676-680.

OTHER

Khan, H.Y., Nagasaka, M., Aboukameel, A., Alkhalili, O., Uddin, Md.H., Bannoura, S., Mzannar, Y., Azar, I., Beal, E., Tobon, M., et al.(2023). Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers . bioRxiv.